Stay updated with breaking news from Mpku. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Synlogic Inc. jolted Wall Street with news that the firm is scrapping for futility Synpheny-3, its pivotal study with labafenogene marselecobac (SYNB-1934) for phenylketonuria, and will evaluate strategic options. Shares of the Cambridge, Mass.-based firm (NASDAQ:SYBX) fell 48.7%, or $1.68, to end Feb. 9 at $1.77. Synlogic will cease operations and reduce its workforce by more than 90%, retaining only certain employees to help with the wind-down. ....
The state where a baby is born determines what serious and rare disorders he or she will be screened for shortly after birth. It’s a patchwork of policies across the country that could have dire consequences. Some parents call it death by ZIP code. ....